UnknownPhase 4ketamine

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

NCT ID

NCT02610712

Target Enrollment

20 participants

Start Date

2014-05

About This Study

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

Conditions Studied

Depressive Disorder, Treatment-Resistant

Interventions

•Ketamine

Eligibility

Age:18 Years - 65 Years

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Treatment-Resistant Depression (Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies)
* Acceptance of participation via the informed consent

Exclusion Criteria:

* Psychiatric comorbidity (except anxiety related disorders)
* Substance abuse or dependence in the previous 3 months
* Evidence of structural abnormalities in brain imaging
* Pregnancy
* Previous hypersensitivity to ketamine
* Heart failure or insufficiency
* Familial or personal history of psychosis
* Glaucoma
* Major neurological disease
* Uncontrolled systemic arterial hypertension
* MRI contraindications
* Non-acceptance of participation via informed consent

Study Locations (1)

National Institute of Neurology and Neurosurgery